These findings define FAT10 as the therapeutic candidate to treat heart disorders, including cyanotic congenital heart disease, pulmonary hypertension, cardiac hypertrophy, heart failure, and atherosclerosis, that are associated with hypoxia-induced apoptosis. The gene discussed is UBD; the disease is cardiac hypertrophy.